Application of bosutinib as enzyme inhibitor of ASPH
作者： Shen Feng , Wang Haibo
DOI:
关键词:
摘要: The invention discloses application of bosutinib as an enzyme inhibitor aspartate beta-hydroxylase (ASPH). can be used for preparing drugs treatment diseases associated with ASPH overexpression. are cancer, liver fibrosis and cirrhosis. cancer includes hepatoma, intrahepatic cholangiocarcinoma, glioblastoma, small cell lung colon pancreatic cancer. A compound capable being bound to the activity structural domain is obtained by virtual screening protein three-dimensional structure, that is, bosutinib. inhibit enzymatic activity, inhibition rate 78.1% at 100 [mu]M. restrain proliferation HepG2, Hep3B Huh7 hepatoma carcinoma cells, IC50values 6.98 [mu]M, 9.52 [mu]M 13.13 respectively.
lens.org 参考文章(5)
Neil Beeharry, Timothy Yen, Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control ,(2014)
Hsin-Jung Lee, Yung-Ming Jeng, Yu-Ling Chen, Ling Chung, Ray-Hwang Yuan, Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma Carcinogenesis. ,vol. 35, pp. 769- 775 ,(2014) , 10.1093/CARCIN/BGT372
Luca Mologni, Carlo Gambacorti, Pharmaceutical combinations for the treatment of cancer ,(2009)
Qingzhong Kong, Enxiang Liu, Bosutinib sustained release implant for treating solid tumors ,(2008)
Ono Kazuhisa, Fujimura Takashi, Kawamoto Masaji, Hirakawa Noriko, Baba Kenji, ANTICANCER AGENT ACTION ENHANCING MATERIAL AND ANTICANCER AGENT KIT INCLUDING THE SAME ,(2018)